在肺动脉高血压中非编码RNA网络
Bing Chen1, Yu Xia2, Yanjiao Jiang2
1Department of Pharmacy, The Affiliated Lianyungang Hospital of Xuzhou Medical University/The First People's Hospital of Lianyungang, Lianyungang, China, 18302081071@163.com.
Pharmacology
|September 29, 2024
概括
肺动脉高血压 (PAH) 需要新的治疗方法. 非编码RNAs (ncRNAs),如lncRNAs,circRNAs和miRNAs是PAH发展的关键,并显示出作为生物标志物和治疗点的前景.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 肺动脉高血压 (PAH) 是一种严重的心血管疾病,其特点是肺动脉压力和抵抗力增加.
- 目前的PAH疗法不足,重点是血管扩张,而不是逆转潜在的血管改造.
- 对于有效的PAH治疗,仍然存在未得到满足的临床需求,需要新的治疗策略.
研究的目的:
- 审查最近在理解非编码RNAs (ncRNAs) 在PAH病变发生中的作用方面的进展.
- 探索各种ncRNA,包括lncRNA,circRNA,miRNA和piRNA在疾病发展中的潜力.
- 讨论ncRNAs作为PAH中的生物标志物和治疗点的挑战和未来方向.
主要方法:
- 关于ncRNAs和PAH的最新科学出版物的文献综述.
- 在肺血管改造中分析ncRNAs的调节机制.
- 综合目前关于ncRNA在PAH中的表达和功能的知识.
主要成果:
- 非编码RNAs (ncRNAs) 在PAH的发生和发展中发挥着关键作用.
- 特定的ncRNAs,如长非编码RNAs (lncRNAs),圆形RNAs (circRNAs),microRNAs (miRNAs) 和PIWI相互作用RNAs (piRNAs),都与PAH病变产生有关.
- 这些ncRNAs通过包括染色体修饰,转录调节和翻译后修饰在内的机制来调节PAH.
结论:
- 对于开发PAH的新型诊断生物标志物来说,ncRNAs是一个有前途的领域.
- 向ncRNAs提供了一种潜在的治疗策略,以解决PAH治疗中的未满足需求.
- 对ncRNA功能和相互作用的进一步研究对于推进PAH治疗至关重要.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
152
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
152
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
144
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
144
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Protein Networks
3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K


